Global Benign Prostatic Hyperplasia Treatment Market Size, Status and Forecast 2024-2031

Report ID: 934510 | Published Date: Jan 2025 | No. of Page: 121 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
        1.2.2 Drug Class
        1.2.3 Minimally Invasive Surgeries
        1.2.4 Laser Therapy
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Benign Prostatic Hyperplasia Treatment Market Share by Application: 2016 VS 2021 VS 2027
        1.3.2 Hospitals
        1.3.3 Ambulatory Surgical Centers
        1.3.4 Specialty Clinics
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered

2 Global Growth Trends
    2.1 Global Benign Prostatic Hyperplasia Treatment Market Perspective (2016-2027)
    2.2 Benign Prostatic Hyperplasia Treatment Growth Trends by Regions
        2.2.1 Benign Prostatic Hyperplasia Treatment Market Size by Regions: 2016 VS 2021 VS 2027
        2.2.2 Benign Prostatic Hyperplasia Treatment Historic Market Share by Regions (2016-2021)
        2.2.3 Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Regions (2022-2027)
    2.3 Benign Prostatic Hyperplasia Treatment Industry Dynamic
        2.3.1 Benign Prostatic Hyperplasia Treatment Market Trends
        2.3.2 Benign Prostatic Hyperplasia Treatment Market Drivers
        2.3.3 Benign Prostatic Hyperplasia Treatment Market Challenges
        2.3.4 Benign Prostatic Hyperplasia Treatment Market Restraints

3 Competition Landscape by Key Players
    3.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue
        3.1.1 Global Top Benign Prostatic Hyperplasia Treatment Players by Revenue (2016-2021)
        3.1.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Players (2016-2021)
    3.2 Global Benign Prostatic Hyperplasia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    3.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Treatment Revenue
    3.4 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio
        3.4.1 Global Benign Prostatic Hyperplasia Treatment Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Treatment Revenue in 2020
    3.5 Benign Prostatic Hyperplasia Treatment Key Players Head office and Area Served
    3.6 Key Players Benign Prostatic Hyperplasia Treatment Product Solution and Service
    3.7 Date of Enter into Benign Prostatic Hyperplasia Treatment Market
    3.8 Mergers & Acquisitions, Expansion Plans

4 Benign Prostatic Hyperplasia Treatment Breakdown Data by Type
    4.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Type (2016-2021)
    4.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Type (2022-2027)

5 Benign Prostatic Hyperplasia Treatment Breakdown Data by Application
    5.1 Global Benign Prostatic Hyperplasia Treatment Historic Market Size by Application (2016-2021)
    5.2 Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Application (2022-2027)

6 North America
    6.1 North America Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
    6.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Type
        6.2.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
        6.2.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
        6.2.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
    6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Application
        6.3.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
        6.3.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
        6.3.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
    6.4 North America Benign Prostatic Hyperplasia Treatment Market Size by Country
        6.4.1 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
        6.4.2 North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
        6.4.3 United States
        6.4.4 Canada

7 Europe
    7.1 Europe Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
    7.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type
        7.2.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
        7.2.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
        7.2.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
    7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application
        7.3.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
        7.3.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
        7.3.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
    7.4 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country
        7.4.1 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
        7.4.2 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic

8 Asia-Pacific
    8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
    8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type
        8.2.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
        8.2.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
        8.2.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
    8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application
        8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
        8.3.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
        8.3.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
    8.4 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region
        8.4.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2016-2021)
        8.4.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2022-2027)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia

9 Latin America
    9.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
    9.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type
        9.2.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
        9.2.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
        9.2.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
    9.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application
        9.3.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
        9.3.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
        9.3.3 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
    9.4 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country
        9.4.1 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
        9.4.2 Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
        9.4.3 Mexico
        9.4.4 Brazil

10 Middle East & Africa
    10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size (2016-2027)
    10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type
        10.2.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021)
        10.2.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027)
        10.2.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2027)
    10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application
        10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021)
        10.3.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027)
        10.3.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2027)
    10.4 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country
        10.4.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021)
        10.4.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE

11 Key Players Profiles
    11.1 Abbott
        11.1.1 Abbott Company Details
        11.1.2 Abbott Business Overview
        11.1.3 Abbott Benign Prostatic Hyperplasia Treatment Introduction
        11.1.4 Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.1.5 Abbott Recent Development
    11.2 Allergan plc
        11.2.1 Allergan plc Company Details
        11.2.2 Allergan plc Business Overview
        11.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Introduction
        11.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.2.5 Allergan plc Recent Development
    11.3 Astellas Pharma
        11.3.1 Astellas Pharma Company Details
        11.3.2 Astellas Pharma Business Overview
        11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Introduction
        11.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.3.5 Astellas Pharma Recent Development
    11.4 Asahi Kasei Corporation
        11.4.1 Asahi Kasei Corporation Company Details
        11.4.2 Asahi Kasei Corporation Business Overview
        11.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Introduction
        11.4.4 Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.4.5 Asahi Kasei Corporation Recent Development
    11.5 Boehringer Ingelheim GmbH
        11.5.1 Boehringer Ingelheim GmbH Company Details
        11.5.2 Boehringer Ingelheim GmbH Business Overview
        11.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Introduction
        11.5.4 Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.5.5 Boehringer Ingelheim GmbH Recent Development
    11.6 GlaxoSmithKline
        11.6.1 GlaxoSmithKline Company Details
        11.6.2 GlaxoSmithKline Business Overview
        11.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Introduction
        11.6.4 GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.6.5 GlaxoSmithKline Recent Development
    11.7 Pfizer
        11.7.1 Pfizer Company Details
        11.7.2 Pfizer Business Overview
        11.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Introduction
        11.7.4 Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.7.5 Pfizer Recent Development
    11.8 Sanofi
        11.8.1 Sanofi Company Details
        11.8.2 Sanofi Business Overview
        11.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Introduction
        11.8.4 Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.8.5 Sanofi Recent Development
    11.9 Teva Pharmaceutical Industries
        11.9.1 Teva Pharmaceutical Industries Company Details
        11.9.2 Teva Pharmaceutical Industries Business Overview
        11.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Introduction
        11.9.4 Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.9.5 Teva Pharmaceutical Industries Recent Development
    11.10 Merck
        11.10.1 Merck Company Details
        11.10.2 Merck Business Overview
        11.10.3 Merck Benign Prostatic Hyperplasia Treatment Introduction
        11.10.4 Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.10.5 Merck Recent Development
    11.11 Boston Scientific Corporation
        11.11.1 Boston Scientific Corporation Company Details
        11.11.2 Boston Scientific Corporation Business Overview
        11.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Introduction
        11.11.4 Boston Scientific Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.11.5 Boston Scientific Corporation Recent Development
    11.12 Teleflex Incorporated
        11.12.1 Teleflex Incorporated Company Details
        11.12.2 Teleflex Incorporated Business Overview
        11.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Introduction
        11.12.4 Teleflex Incorporated Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.12.5 Teleflex Incorporated Recent Development
    11.13 Endo International
        11.13.1 Endo International Company Details
        11.13.2 Endo International Business Overview
        11.13.3 Endo International Benign Prostatic Hyperplasia Treatment Introduction
        11.13.4 Endo International Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.13.5 Endo International Recent Development
    11.14 Urologix
        11.14.1 Urologix Company Details
        11.14.2 Urologix Business Overview
        11.14.3 Urologix Benign Prostatic Hyperplasia Treatment Introduction
        11.14.4 Urologix Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.14.5 Urologix Recent Development
    11.15 LISA Laser
        11.15.1 LISA Laser Company Details
        11.15.2 LISA Laser Business Overview
        11.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Introduction
        11.15.4 LISA Laser Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.15.5 LISA Laser Recent Development
    11.16 Olympus
        11.16.1 Olympus Company Details
        11.16.2 Olympus Business Overview
        11.16.3 Olympus Benign Prostatic Hyperplasia Treatment Introduction
        11.16.4 Olympus Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
        11.16.5 Olympus Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details
List of Tables
    Table 1. Global Benign Prostatic Hyperplasia Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
    Table 2. Key Players of Drug Class
    Table 3. Key Players of Minimally Invasive Surgeries
    Table 4. Key Players of Laser Therapy
    Table 5. Key Players of Others
    Table 6. Global Benign Prostatic Hyperplasia Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
    Table 7. Global Benign Prostatic Hyperplasia Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
    Table 8. Global Benign Prostatic Hyperplasia Treatment Market Size by Regions (2016-2021) & (US$ Million)
    Table 9. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions (2016-2021)
    Table 10. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
    Table 11. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions (2022-2027)
    Table 12. Benign Prostatic Hyperplasia Treatment Market Trends
    Table 13. Benign Prostatic Hyperplasia Treatment Market Drivers
    Table 14. Benign Prostatic Hyperplasia Treatment Market Challenges
    Table 15. Benign Prostatic Hyperplasia Treatment Market Restraints
    Table 16. Global Benign Prostatic Hyperplasia Treatment Revenue by Players (2016-2021) & (US$ Million)
    Table 17. Global Benign Prostatic Hyperplasia Treatment Market Share by Players (2016-2021)
    Table 18. Global Top Benign Prostatic Hyperplasia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia Treatment as of 2020)
    Table 19. Ranking of Global Top Benign Prostatic Hyperplasia Treatment Companies by Revenue (US$ Million) in 2020
    Table 20. Global 5 Largest Players Market Share by Benign Prostatic Hyperplasia Treatment Revenue (CR5 and HHI) & (2016-2021)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Benign Prostatic Hyperplasia Treatment Product Solution and Service
    Table 23. Date of Enter into Benign Prostatic Hyperplasia Treatment Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 26. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2016-2021)
    Table 27. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
    Table 28. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
    Table 29. Global Benign Prostatic Hyperplasia Treatment Market Size Share by Application (2016-2021) & (US$ Million)
    Table 30. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2016-2021)
    Table 31. Global Benign Prostatic Hyperplasia Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
    Table 32. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
    Table 33. North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 34. North America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 35. North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 36. North America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 37. North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 38. North America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 39. Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 40. Europe Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 41. Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 42. Europe Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 43. Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 44. Europe Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 45. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 46. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 47. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 48. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 49. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2016-2021) & (US$ Million) 
    Table 50. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region (2022-2027) & (US$ Million) 
    Table 51. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 52. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 53. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 54. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 55. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 56. Latin America Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 57. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2016-2021) (US$ Million)
    Table 58. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Type (2022-2027) & (US$ Million)
    Table 59. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2016-2021) (US$ Million)
    Table 60. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Application (2022-2027) & (US$ Million)
    Table 61. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2016-2021) & (US$ Million) 
    Table 62. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country (2022-2027) & (US$ Million) 
    Table 63. Abbott Company Details
    Table 64. Abbott Business Overview
    Table 65. Abbott Benign Prostatic Hyperplasia Treatment Product
    Table 66. Abbott Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 67. Abbott Recent Development
    Table 68. Allergan plc Company Details
    Table 69. Allergan plc Business Overview
    Table 70. Allergan plc Benign Prostatic Hyperplasia Treatment Product
    Table 71. Allergan plc Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 72. Allergan plc Recent Development
    Table 73. Astellas Pharma Company Details
    Table 74. Astellas Pharma Business Overview
    Table 75. Astellas Pharma Benign Prostatic Hyperplasia Treatment Product
    Table 76. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 77. Astellas Pharma Recent Development
    Table 78. Asahi Kasei Corporation Company Details
    Table 79. Asahi Kasei Corporation Business Overview
    Table 80. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product
    Table 81. Asahi Kasei Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 82. Asahi Kasei Corporation Recent Development
    Table 83. Boehringer Ingelheim GmbH Company Details
    Table 84. Boehringer Ingelheim GmbH Business Overview
    Table 85. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product
    Table 86. Boehringer Ingelheim GmbH Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 87. Boehringer Ingelheim GmbH Recent Development
    Table 88. GlaxoSmithKline Company Details
    Table 89. GlaxoSmithKline Business Overview
    Table 90. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product
    Table 91. GlaxoSmithKline Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 92. GlaxoSmithKline Recent Development
    Table 93. Pfizer Company Details
    Table 94. Pfizer Business Overview
    Table 95. Pfizer Benign Prostatic Hyperplasia Treatment Product
    Table 96. Pfizer Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 97. Pfizer Recent Development
    Table 98. Sanofi Company Details
    Table 99. Sanofi Business Overview
    Table 100. Sanofi Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 101. Sanofi Recent Development
    Table 102. Teva Pharmaceutical Industries Company Details
    Table 103. Teva Pharmaceutical Industries Business Overview
    Table 104. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product
    Table 105. Teva Pharmaceutical Industries Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 106. Teva Pharmaceutical Industries Recent Development
    Table 107. Merck Company Details
    Table 108. Merck Business Overview
    Table 109. Merck Benign Prostatic Hyperplasia Treatment Product
    Table 110. Merck Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 111. Merck Recent Development
    Table 112. Boston Scientific Corporation Company Details
    Table 113. Boston Scientific Corporation Business Overview
    Table 114. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product
    Table 115. Boston Scientific Corporation Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 116. Boston Scientific Corporation Recent Development
    Table 117. Teleflex Incorporated Company Details
    Table 118. Teleflex Incorporated Business Overview
    Table 119. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product
    Table 120. Teleflex Incorporated Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 121. Teleflex Incorporated Recent Development
    Table 122. Endo International Company Details
    Table 123. Endo International Business Overview
    Table 124. Endo International Benign Prostatic Hyperplasia Treatment Product
    Table 125. Endo International Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 126. Endo International Recent Development
    Table 127. Urologix Company Details
    Table 128. Urologix Business Overview
    Table 129. Urologix Benign Prostatic Hyperplasia Treatment Product
    Table 130. Urologix Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 131. Urologix Recent Development
    Table 132. LISA Laser Company Details
    Table 133. LISA Laser Business Overview
    Table 134. LISA Laser Benign Prostatic Hyperplasia Treatment Product
    Table 135. LISA Laser Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 136. LISA Laser Recent Development
    Table 137. Olympus Company Details
    Table 138. Olympus Business Overview
    Table 139. Olympus Benign Prostatic Hyperplasia Treatment Product
    Table 140. Olympus Revenue in Benign Prostatic Hyperplasia Treatment Business (2016-2021) & (US$ Million)
    Table 141. Olympus Recent Development
    Table 142. Research Programs/Design for This Report
    Table 143. Key Data Information from Secondary Sources
    Table 144. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Benign Prostatic Hyperplasia Treatment Market Share by Type: 2020 VS 2027
    Figure 2. Drug Class Features
    Figure 3. Minimally Invasive Surgeries Features
    Figure 4. Laser Therapy Features
    Figure 5. Others Features
    Figure 6. Global Benign Prostatic Hyperplasia Treatment Market Share by Application: 2020 VS 2027
    Figure 7. Hospitals Case Studies
    Figure 8. Ambulatory Surgical Centers Case Studies
    Figure 9. Specialty Clinics Case Studies
    Figure 10. Others Case Studies
    Figure 11. Benign Prostatic Hyperplasia Treatment Report Years Considered
    Figure 12. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
    Figure 13. Global Benign Prostatic Hyperplasia Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
    Figure 14. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions: 2020 VS 2027
    Figure 15. Global Benign Prostatic Hyperplasia Treatment Market Share by Regions (2022-2027)
    Figure 16. Global Benign Prostatic Hyperplasia Treatment Market Share by Players in 2020
    Figure 17. Global Top Benign Prostatic Hyperplasia Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia Treatment as of 2020
    Figure 18. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Treatment Revenue in 2020
    Figure 19. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2016-2021)
    Figure 20. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type (2022-2027)
    Figure 21. North America Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 22. North America Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
    Figure 23. North America Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
    Figure 24. North America Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
    Figure 25. United States Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 26. Canada Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 27. Europe Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 28. Europe Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
    Figure 29. Europe Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
    Figure 30. Europe Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
    Figure 31. Germany Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 32. France Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 33. U.K. Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 34. Italy Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 35. Russia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 36. Nordic Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 37. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 38. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
    Figure 39. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
    Figure 40. Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Share by Region (2016-2027)
    Figure 41. China Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 42. Japan Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 43. South Korea Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 44. Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 45. India Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 46. Australia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 47. Latin America Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 48. Latin America Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
    Figure 49. Latin America Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
    Figure 50. Latin America Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
    Figure 51. Mexico Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 52. Brazil Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 53. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 54. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Type (2016-2027)
    Figure 55. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Application (2016-2027)
    Figure 56. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Share by Country (2016-2027)
    Figure 57. Turkey Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 58. Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 59. UAE Benign Prostatic Hyperplasia Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
    Figure 60. Abbott Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 61. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 62. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 63. Asahi Kasei Corporation Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 64. Boehringer Ingelheim GmbH Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 65. GlaxoSmithKline Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 66. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 67. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 68. Teva Pharmaceutical Industries Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 69. Merck Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 70. Boston Scientific Corporation Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 71. Teleflex Incorporated Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 72. Endo International Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 73. Urologix Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 74. LISA Laser Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 75. Olympus Revenue Growth Rate in Benign Prostatic Hyperplasia Treatment Business (2016-2021)
    Figure 76. Bottom-up and Top-down Approaches for This Report
    Figure 77. Data Triangulation
    Figure 78. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Abbott
Allergan plc
Astellas Pharma
Asahi Kasei Corporation
Boehringer Ingelheim GmbH
GlaxoSmithKline
Pfizer
Sanofi
Teva Pharmaceutical Industries
Merck
Boston Scientific Corporation
Teleflex Incorporated
Endo International
Urologix
LISA Laser
Olympus
Frequently Asked Questions
Benign Prostatic Hyperplasia Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Benign Prostatic Hyperplasia Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Benign Prostatic Hyperplasia Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports